Members of the Bcl-2-protein family are key controllers of apoptotic cell death. The family is
divided into antiapoptotic (including Bcl-2 itself, Bcl-xL, Mcl-1, etc.) and proapoptotic …

Simple Summary The development of BCL-2 inhibitors as a pivotal approach in cancer
treatment lies in their ability to effectively trigger apoptosis in tumor cells. Venetoclax, a …

The treatment of acute leukemia is challenging because of the genetic heterogeneity
between and within patients. Leukemic stem cells (LSCs) are relatively drug-resistant and …

Central nervous system (CNS) injuries, including traumatic brain injury (TBI), intracerebral
hemorrhage (ICH) and ischemic stroke, are the most common cause of death and disability …

Acute myeloid leukemia (AML) is a disease that mainly affects elderly patients who are more
often unfit for intensive chemotherapy (median age of diagnosis is 68). The regimens …

Overexpression of BCL-xL and BCL-2 play key roles in tumorigenesis and cancer drug
resistance. Advances in PROTAC technology facilitated recent development of the first BCL …

Simple Summary Venetoclax–azacitidine is a new standard for elderly or unfit acute myeloid
leukemia patients. Nevertheless, resistance remains a matter of concern. The main genetic …

Acute myeloid leukaemia (AML) is a highly aggressive and devastating malignancy of the
bone marrow and blood. For decades, intensive chemotherapy has been the frontline …

Abstract BTK inhibitors, Bcl-2 inhibitors, and other targeted therapies have significantly
improved the outcomes of patients with chronic lymphocytic leukemia (CLL). With increased …

Acute myeloid leukemia (AML) is often associated with poor prognosis and survival. Small
molecule inhibitors, though widening the treatment landscape, have limited monotherapy …